Reviewing G1 THERAPEUTICS (GTHX) and Its Rivals

G1 THERAPEUTICS (NASDAQ: GTHX) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare G1 THERAPEUTICS to related businesses based on the strength of its dividends, profitability, valuation, risk, earnings, analyst recommendations and institutional ownership.


This table compares G1 THERAPEUTICS and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
G1 THERAPEUTICS Competitors -5,311.19% -218.06% -39.34%

Analyst Ratings

This is a breakdown of recent ratings and target prices for G1 THERAPEUTICS and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
G1 THERAPEUTICS 0 0 4 0 3.00
G1 THERAPEUTICS Competitors 857 3201 11603 231 2.71

G1 THERAPEUTICS presently has a consensus target price of $29.75, indicating a potential upside of 50.40%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.91%. Given G1 THERAPEUTICS’s stronger consensus rating and higher probable upside, research analysts clearly believe G1 THERAPEUTICS is more favorable than its peers.

Earnings & Valuation

This table compares G1 THERAPEUTICS and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
G1 THERAPEUTICS Competitors $284.28 million $34.29 million 80.70

G1 THERAPEUTICS’s peers have higher revenue and earnings than G1 THERAPEUTICS. G1 THERAPEUTICS is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

43.3% of G1 THERAPEUTICS shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


G1 THERAPEUTICS beats its peers on 6 of the 10 factors compared.


G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with's FREE daily email newsletter.

Leave a Reply